Patients maintained on TPO-RA have had sustained response rates of up to 70% at 6 months, but vein thrombosis rates are increased with these agents, and annualized thrombosis rates appear to be 2–3 times higher in patients treated with TPO-RA than in other ITP patients [5,7]. The gene discussed is TPO; the disease is Venous thrombosis.